Polygenic Scores to Assess Atherosclerotic Cardiovascular Disease Risk: Clinical Perspectives and Basic Implications - PubMed

Polygenic Scores to Assess Atherosclerotic Cardiovascular Disease Risk: Clinical Perspectives and Basic Implications - PubMed

Polygenic Scores to Assess Atherosclerotic Cardiovascular Disease Risk: Clinical Perspectives and Basic Implications

Krishna G Aragam 1, Pradeep Natarajan 1

Affiliations 

• PMID: 32324503
 
• DOI: 10.1161/CIRCRESAHA.120.315928

Abstract

An individual's susceptibility to atherosclerotic cardiovascular disease is influenced by numerous clinical and lifestyle factors, motivating the multifaceted approaches currently endorsed for primary and secondary cardiovascular disease prevention. With growing knowledge of the genetic basis of atherosclerotic cardiovascular disease-in particular, coronary artery disease-and its contribution to disease pathogenesis, there is increased interest in understanding the potential clinical utility of a genetic predictor that might further refine the assessment and management of atherosclerotic cardiovascular disease risk. Rapid scientific and technological advances have enabled widespread genotyping efforts and dynamic research in the field of coronary artery disease genetic risk prediction. In this review, we describe how genomic analyses of coronary artery disease have been leveraged to create polygenic risk scores. We then discuss evaluations of the clinical utility of these scores, pertinent mechanistic insights gleaned, and practical considerations relevant to the implementation of polygenic risk scores in the health care setting.

Keywords: atherosclerosis; cardiovascular disease; coronary artery disease; genome-wide association study; genotype.

Similar articles

• Inclusion of stroke in cardiovascular risk prediction instruments: a statement for healthcare professionals from the American Heart Association/American Stroke Association.

  Lackland DT, Elkind MS, D'Agostino R Sr, Dhamoon MS, Goff DC Jr, Higashida RT, McClure LA, Mitchell PH, Sacco RL, Sila CA, Smith SC Jr, Tanne D, Tirschwell DL, Touzé E, Wechsler LR; American Heart Association Stroke Council; Council on Epidemiology and Prevention; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research.Stroke. 2012 Jul;43(7):1998-2027. doi: 10.1161/STR.0b013e31825bcdac. Epub 2012 May 24.PMID: 22627990
• Genetic Risk Prediction for Primary and Secondary Prevention of Atherosclerotic Cardiovascular Disease: an Update.

  Labos C, Thanassoulis G.Curr Cardiol Rep. 2018 Mar 24;20(5):36. doi: 10.1007/s11886-018-0980-0.PMID: 29574623 Review.
• How Genomics Is Personalizing the Management of Dyslipidemia and Cardiovascular Disease Prevention.

  Benes LB, Brandt DJ, Brandt EJ, Davidson MH.Curr Cardiol Rep. 2018 Oct 17;20(12):138. doi: 10.1007/s11886-018-1079-3.PMID: 30328514 Review.
• Polygenic Scores in Epidemiology: Risk Prediction, Etiology, and Clinical Utility.

  Maher BS.Curr Epidemiol Rep. 2015 Dec;2(4):239-244. doi: 10.1007/s40471-015-0055-3. Epub 2015 Sep 28.PMID: 26664818 Free PMC article.
• AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.

  Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, Grunberger G, Guerin CK, Bell DSH, Mechanick JI, Pessah-Pollack R, Wyne K, Smith D, Brinton EA, Fazio S, Davidson M.Endocr Pract. 2017 Apr;23(Suppl 2):1-87. doi: 10.4158/EP171764.APPGL.PMID: 28437620